A Phase 1, Open-label Study of TAK-659 as a Single Agent in Adult East Asian Patients With Non-Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 09 Sep 2018
At a glance
- Drugs TAK 659 (Primary)
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda Oncology; Takeda Pharma
- 08 Sep 2017 Status changed from not yet recruiting to recruiting.
- 11 Aug 2017 Planned initiation date changed from 2 Aug 2017 to 31 Aug 2017.
- 07 Aug 2017 New trial record